CureXcell™ is comprised of a mixture of white blood cells including monocytes/macrophages, neutrophils and lymphocytes obtained from young (18-40 yrs old) healthy donor blood which is activated by a safe and simple yet patented process. CureXcell™ replenishes the imbalanced inflammatory environment in the non-healing wound with functionally-active immune cells which release the necessary growth factors and are capable of phagocytosis of bacteria and dead cells in the wound bed, processes that are important for healing.
By recreating the natural environment for wound healing, the appropriate cell activities and factor secretions are maintained as required during each of the stages of wound healing and assist in the wound’s debridement. What gives CureXcell™ an additional breakthrough edge is the precise balance of important immune cells in an activated state required to initiate the healing process. Once the process is started, CureXcell™ stimulates the patient’s own body to complete the healing process
CureXcell™ comprises a diverse array of active cells and has been shown to be effective to treat different wound types with different degrees of severity. Among the mixture of cells, the activated monocyte (macrophage) plays a central role in wound healing. The macrophage takes part in all stages of the complex sequence of cellular and molecular processes involved in wound healing such as cell migration, inflammation, angiogenesis, collagen synthesis and deposition, and re-epithelialization. Upon initiation of the inflammation stage, the macrophages secrete IL-1 that induces the rapid recruitment of inflammation cells from the circulation into the wound [1-3]. By employing their phagocytic capabilities, they help in the digestion of bacteria and debridement [4] and, in the later stages of the wound-healing process, they secrete IL-6, which is believed to influence endothelial cell proliferation and the initiation of angiogenesis [5-7]. The macrophage serves as the coordinator of this proliferative process, by producing growth factors such as PDGF BB, TGF-a, TGF-b1, VEGF, FGF, EGF and IGF-1, necessary in the wound healing process [8,2,9]. It appears that the age of the macrophages play an important role in the process [10]. By producing CureXcell™ from young (18-40 years old) healthy donor blood, the effectiveness of the treatment is significantly enhanced.
References:
1. Di Padova F, Pozzi C, Tondre MY et al. Selective and early increase of IL-1 inhibitors, IL- 6 and cortisol after elective surgery. Clin Exp Immunol 1991; 85:137–42.
2. Rappolee DA, Werb Z. Macrophage derived growth factors. In: Evans DA, Patel VL eds. Current topics in microbiology and immunology.Berlin: Springer-Verlag, 1992; 181:87–140.
3. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2:108–15.
4. Aderem A, Underhill DM. Mechanisms of phagocytosis in monocytes/macrophages. Annu Rev Immunol 1999; 17:593–623. © 2002 Blackwell Science Ltd, Clinical and Experimental Immunology, 128:59–66
5. Nishida T, Nakamura M, Mishima H et al. Interleukin-6, 11. Facilitates corneal epithelial wound closure in vivo. Arch Ophthalmol 1992 110:1292–93.
6. Romeo MB, Reichner JS, Albina JE. Interleukin-6 activity in wounds. Am J Physiol 1994; 266:R1840–R1844.
7. Wong GG, Clark SC. Multiple actions of interleukin 6 with a cytokine network. Immunol Today 1988; 9:137–9
8. Di Pietro LA. Wound healing: the role of macrophage and other immune cells. Shock 1995; 4:233–40
9. Singer AJ, Clark RAF. Cutaneous wound healing. N Engl J Med 1999;341:738–46.
10. Danon D, Kowach MA, Roth GS. Promotion of wound repair in old mice by local injection of monocytes/macrophages. Proc Natl Acad Sci USA 1989; 86:2018–20.
